These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27863749)

  • 1. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals.
    Ippolito G; Antonelli G
    Clin Microbiol Infect; 2016 Oct; 22(10):824-825. PubMed ID: 27863749
    [No Abstract]   [Full Text] [Related]  

  • 2. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges.
    Thompson A; Patel K; Tillman H; McHutchison JG
    J Hepatol; 2009 Jan; 50(1):184-94. PubMed ID: 19022518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
    Ta K; Zehtabchi S
    Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
    [No Abstract]   [Full Text] [Related]  

  • 4. The safety of daclatasvir for the treatment of hepatitis C.
    Jafri SM; Gordon SC
    Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.
    Arends JE; Kracht PA; Hoepelman AI;
    Clin Microbiol Infect; 2016 Oct; 22(10):846-852. PubMed ID: 27297320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
    Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
    Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
    [No Abstract]   [Full Text] [Related]  

  • 9. The gap between registration trials and real world in hepatitis C is closing.
    Berden FA; Vuik FE; Drenth JP; Kievit W
    Dig Liver Dis; 2017 Apr; 49(4):454-455. PubMed ID: 28190697
    [No Abstract]   [Full Text] [Related]  

  • 10. Worth the wait. New, more effective therapies for hepatitis C are on the way.
    Learned J
    Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021
    [No Abstract]   [Full Text] [Related]  

  • 11. The new era of hepatitis C treatment: still the tip of the iceberg?
    Gasbarrini A; Ponziani FR; Annichiarico BE; Siciliano M; Craxì A
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2271-4. PubMed ID: 24065217
    [No Abstract]   [Full Text] [Related]  

  • 12. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
    Suda G; Yamasaki K; Sakamoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
    [No Abstract]   [Full Text] [Related]  

  • 14. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging treatments for hepatitis C.
    Flisiak R; Jaroszewicz J; Parfieniuk-Kowerda A
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):461-75. PubMed ID: 24102413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.
    Gentile I; Buonomo AR; Zappulo E; Coppola N; Borgia G
    Expert Rev Anti Infect Ther; 2014 Oct; 12(10):1179-86. PubMed ID: 25096404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches.
    Yeung E; Chung RT
    J Hepatol; 2005 Nov; 43(5):748-50. PubMed ID: 16171895
    [No Abstract]   [Full Text] [Related]  

  • 20. Caution with the use of the new direct acting antivirals in the hepatitis C virus related renal disease.
    Gomis A; Díaz M; de Lorenzo A; Ruiz-Roso G; Liaño F
    Nefrologia; 2016; 36(6):713-715. PubMed ID: 27575928
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.